Table 3.
Impact of the Oncotype DX Recurrence Score results on patients’ treatment decisions regarding adjuvant therapy.
| Pre-assay Patient Decisions | Post-assay Patient Decisions | ||||
|---|---|---|---|---|---|
| Observation | 5FU-based Monotherapy | 5FU+Oxaliplatin | Other | Total | |
| Observation | 51 37.0% |
6 4.3% |
7 5.1% |
0 | 64 46.4% |
| 5FU-based Monotherapy | 4 2.9% |
0 | 0 | 0 | 4 2.9% |
| 5FU + Oxaliplatin | 3 2.2% |
2 1.4% |
3 2.2% |
1 0.7% |
9 6.5% |
| Other | 3 2.2% |
1 0.7% |
0 | 1 0.7% |
5 3.6% |
| Undecided | 42 30.4% |
8 5.8% |
5 3.6% |
1 0.7% |
56 40.6% |
| Total | 103 74.6% |
17 12.3% |
15 10.9% |
3 2.2% |
138 100.0% |